Revlimid Fast Track Status Based On Randomized Trial Plan Later Skipped
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Celgene was granted a fast track designation for Revlimid based on plans to conduct a randomized trial that it later put off until after FDA approval, review documents show
You may also be interested in...
Revlimid Lax Teratogenicity Studies Led To Broad Risk Management Plan – FDA
An inadequate reproductive safety assessment of Celgene’s Revlimid was of central concern to FDA during its review of the myelodysplastic syndromes treatment and helped guide post-approval risk management requirements, review documents show.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011